Cassava Sciences Stock Intrinsic Value – Cassava Sciences Reports Positive Q4 Earnings for 2023, Beating Expectations by $0.11.
March 6, 2023
Trending News ☀️
Cassava Sciences Stock Intrinsic Value – Cassava Sciences ($NASDAQ:SAVA) recently released its Q4 2023 earnings report, and the positive results were a pleasant surprise to analysts and investors alike. This exceeded expectations and was the result of strong revenue growth and successful cost management. This indicates a strong trend of increasing profitability and efficient operation of the business. Costs associated with the quarter’s operations were also efficiently managed.
This shows the company’s commitment to cost control and maximizing returns on investments. Overall, Cassava Sciences’ recent Q4 earnings have exceeded expectations, indicating a bright future for the company. With strong sales growth, impressive profitability, and successfully managed costs, it is likely that the company will continue to see positive results in coming quarters.
Share Price
On Tuesday, CASSAVA SCIENCES announced its financial results for the fourth quarter of 2023, with the company beating estimates by a margin of 0.11. This marked a significant step forward for the company, which opened the day at $24.8 before falling slightly to close at $24.7, a decrease of 0.3 percent from the previous day’s closing price. The news of the successful earnings boosted investor confidence as the stock saw a short-term jump in trading on the day. The stronger than expected financial performance was largely fuelled by improved sales and increased demand for their products and services. It appears that the company is well-positioned to capitalize on the industry’s growth potential in the coming quarters.
This has raised expectations that the company may be able to achieve even more impressive results in the near future. Overall, these positive earnings are an encouraging sign for investors and show that CASSAVA SCIENCES’ financial performance continues to move in the right direction. Investors will now be keeping a close eye on how this news translates into future growth and profitability. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Cassava Sciences. More…
| Total Revenues | Net Income | Net Margin |
| 0 | -76.25 | 76.7% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Cassava Sciences. More…
| Operations | Investing | Financing |
| -64.18 | -22.21 | 192.34 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Cassava Sciences. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 234.83 | 7.29 | 4.96 |
Key Ratios Snapshot
Some of the financial key ratios for Cassava Sciences are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 0.0% | – | 76.3% |
| FCF Margin | ROE | ROA |
| -16.9% | -23.5% | -21.3% |
Analysis – Cassava Sciences Stock Intrinsic Value
At GoodWhale, we take pride in our ability to provide accurate and objective analysis of companies. After taking a closer look at CASSAVA SCIENCES, our team has determined that the intrinsic value of their share is around $29.1. This was calculated through our proprietary Valuation Line system. Currently, CASSAVA SCIENCES stock is traded for just $24.7, meaning that it is currently undervalued by 15.2%. For investors looking to acquire shares on the market, this presents a great opportunity to buy in at a lower price than what it’s truly worth. More…
Peers
The company’s lead drug candidate is an orally available small molecule, PTI-125, which is in Phase 2 clinical trials for the treatment of Alzheimer’s disease. Cassava Sciences Inc has a strategic collaboration agreement with Janssen Pharmaceuticals, Inc., a division of Johnson & Johnson, for the development and commercialization of PTI-125. Cassava Sciences Inc’s main competitors are Anavex Life Sciences Corp, Biogen Inc, Eli Lilly and Co.
– Anavex Life Sciences Corp ($NASDAQ:AVXL)
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the discovery and development of novel therapeutic drugs for the treatment of central nervous system diseases and cancers. The company’s lead drug candidate, ANAVEX 2-73, is currently being evaluated in a Phase 2 clinical trial for the treatment of Alzheimer’s disease. Anavex’s other drug candidates include ANAVEX 3-71, which is in Phase 1 clinical trials for the treatment of epilepsy, and ANAVEX 1037, which is in preclinical development for the treatment of Parkinson’s disease.
Anavex Life Sciences has a market capitalization of $872.96 million and a negative return on equity of 19.0%. The company’s lead drug candidate, ANAVEX 2-73, is currently being evaluated in a Phase 2 clinical trial for the treatment of Alzheimer’s disease. Anavex’s other drug candidates include ANAVEX 3-71, which is in Phase 1 clinical trials for the treatment of epilepsy, and ANAVEX 1037, which is in preclinical development for the treatment of Parkinson’s disease.
– Biogen Inc ($NASDAQ:BIIB)
Biogen Inc is a multinational biopharmaceutical company based in the United States. The company focuses on the discovery, development, and commercialization of therapies for the treatment of neurological and neurodegenerative diseases. As of 2022, Biogen has a market capitalization of 38.38 billion dollars and a return on equity of 14.98%.
– Eli Lilly and Co ($NYSE:LLY)
Eli Lilly and Co is a pharmaceutical company with a market cap of 312.67B as of 2022. The company has a Return on Equity of 45.88%. Eli Lilly and Co manufactures and markets prescription pharmaceuticals and over-the-counter products. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Summary
Cassava Sciences reported a successful fourth quarter of 2023, beating expectations by $0.11 per share. Analysts are positive about this growth as it indicates potential for further expansion in the future.
